Immuno-Oncology | Specialty

The Role of Anti-PD-L1 Immunotherapy in Cancer

January 29th 2014

Immunotherapy has become an increasingly appealing therapeutic strategy for patients with cancer, with many late-stage clinical trials demonstrating overall survival (OS) advantages in melanoma and castrationresistant prostate cancer.

NewLink Genetics Pursues Dual Cancer Immunotherapy Platforms

January 20th 2014

Harnessing multiple components of the immune system to fight cancer is the focus of NewLink Genetics' clinical pipeline.

Anti-PD-1 Antibody Pidilizumab Shows Promise in Diffuse Large B-Cell Lymphoma

January 17th 2014

The anti-PD-1 monoclonal antibody pidilizumab showed promising clinical activity and was safely administered to patients with diffuse large B-cell lymphoma after autologous hematopoietic stem-cell transplantation.

Dr. John Marshall Provides Colorectal Cancer Updates

January 17th 2014

John L. Marshall, MD, from Georgetown University Hospital, on the recent advancements in colorectal cancer.

Studies Demonstrate Potential of Immunomodulation as Therapeutic Target in Gynecologic Cancers

January 17th 2014

The renaissance in immunology is already affecting treatment paradigms for a variety of gynecologic cancers, and the impact is only likely to expand.

Kris Provides Insight Into New Drugs for Lung Cancer

January 16th 2014

Mark G. Kris, MD, from the Memorial Sloan-Kettering Cancer Center, describes the new drugs and other emerging trends in lung cancer.

Dr. Piperdi on Immunotherapy in Lung Cancer

January 15th 2014

Bilal Piperdi, MD, Associate Professor of Clinical Medicine, Department of Medicine (Oncology), Albert Einstein College of Medicine, discusses the potential of immunotherapy for the treatment of patients with lung cancer.

Combined Vaccines Improve Survival in Metastatic Pancreatic Cancer

January 14th 2014

Combining two specific anti-cancer vaccines, rather than administering one as monotherapy, doubles the 1-year survival probability in patients with metastatic pancreatic ductal adenocarcinoma (PDAC), according to the results of a phase II study presented January 14.

Tasquinimod Improves OS, PFS in CRPC, Data Show

January 9th 2014

Tasquinimod, an experimental immunotherapy and anti-angiogenic agent, prolongs not just progression-free survival (PFS) but also overall survival (OS) in certain men with castration-resistant prostate cancer

Dr. Rizvi on Pseudo-Progression in Lung Cancer

January 6th 2014

Naiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan-Kettering Cancer Center, discusses the phenomenon of pseudoprogression in patients with lung cancer after they receive immunotherapy treatment.

Dr. Kluger on the Challenges of Treating Melanoma

January 2nd 2014

Harriet Kluger, MD, associate professor of medicine (medical oncology), associate director, Hematology/Oncology Fellowship Program, Yale Cancer Center, discusses the changes and challenges of treating patients with melanoma.

Dr. Loi on the Association Between TILs and Trastuzumab

December 11th 2013

Sherene Loi, MD, PhD, on the association between immune cells and a pathologic complete response in patients with breast cancer after being given chemotherapy and trastuzumab.

Hematologic Immunotherapy Breaks New Ground in Established Field

December 6th 2013

Although immunotherapy advances in solid tumors have captured much attention in recent years, therapeutic strategies that enable the patient's own immune system to battle cancer cells have long been integrated into the treatment of patients with hematologic malignancies.

Dr. Galsky on the Role of Ipilimumab in Bladder Cancer

December 5th 2013

Matthew D. Galsky, MD, assistant professor of medicine, Department of Medicine, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, director, Genitourinary Medical Oncology, Tisch Cancer Institute at Mount Sinai Medical Center, discusses the role of ipilimumab in bladder cancer.

Dr. Balar on Immunotherapy in Bladder Cancer

November 25th 2013

Arjun Balar, MD, assistant professor of medicine, Division of Hematology & Oncology, New York University Cancer Institute, NYU Langone Medical Center, discusses the potential of immunotherapy agents as treatment for bladder cancer.

Novel Vaccine Induces Durable Remissions in Patients With Advanced Lymphoma

November 25th 2013

Immunotherapy can induce regressions of even advanced stage cancers, and many of these patients can have prolonged disease remissions.

Dr. Piperdi on the Stimuvax Vaccine in Lung Cancer

November 20th 2013

Bilal Piperdi, MD, from the Albert Einstein College of Medicine, discussed a trial looking at a vaccine in patients with lung cancer at the 8th Annual New York Lung Cancer Symposium®.

Treating Renal Cell Carcinoma in 2013: An Interview With Sumanta Kumar Pal, MD

November 19th 2013

Over the past few years, seven new drugs have gained approval from the FDA for the treatment of patients with metastatic renal cell carcinoma. Primarily these approaches target angiogenesis and mTOR. The advent of these molecularly targeted therapies has significantly improved the standard of care for patients with RCC.

Multidisciplinary Melanoma Program Facilitates Patient Care and Clinical Research

November 19th 2013

The Malignant Melanoma Program at Wake Forest Baptist Health employs a multidisciplinary approach for the management of patients with all stages of this disease. The goals of the program are centered on unequivocal excellence in all areas of care for patients with malignant melanoma.

Dr. Galsky on Ipilimumab in Bladder Cancer

November 15th 2013

Matthew D. Galsky, MD, from the Tisch Cancer Institute at Mount Sinai Medical Center, explains the mechanism of action of ipilimumab in bladder cancer.